546 results on '"Boos, Joachim"'
Search Results
102. Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia.
103. Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies
104. Feasibility and effects of a home-based intervention using activity trackers on achievement of individual goals, quality of life and motor performance in patients with paediatric cancer
105. Use of PEG-asparaginase in the treatment of patients with solid tumors
106. Determination of ( E)-5-(2-bromovinyl)-2′-deoxyuridine in plasma and urine by capillary electrophoresis
107. Pegaspargase (Polyethylene Glycol-L-Asparaginase): A Viewpoint by Joachim Boos and Herbert Jürgens
108. Objectively measured versus self-reported physical activity in children and adolescents with cancer
109. A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics
110. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years
111. Towards a Model-Based Dose Recommendation for Doxorubicin in Children
112. Improved 6‐year overall survival in AT / RT – results of the registry study Rhabdoid 2007
113. One in Four Questioned Children Faces Problems Regarding Reintegration Into Physical Education at School After Treatment for Pediatric Cancer
114. Motor Performance After Treatment for Pediatric Bone Tumors
115. Incidence and Characteristics of Hypersensitivity Reactions to PEG‐asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP‐BFM ALL 2009 Study Protocol.
116. Investigating the heterogeneity of alkylating agents’ efficacy between genders: A meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
117. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity
118. Toxicity of Very Prolonged Pegasparaginase and Erwinia Asparaginase Courses in Relation to Asparaginase Activity Levels with a Special Focus on Dyslipidemia
119. Motor performance in children and adolescents with cancer at the end of acute treatment phase
120. Abstract 4625: Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study
121. Dosisabhängigkeit der Cisplatin-Ototoxizität
122. Pharmakologische und arzneimittelrechtliche Probleme im Kindesalter
123. Pharmakologische und arzneimittelrechtliche Probleme im Kindesalter
124. Immediate Cooling Does Not Prevent the Ex Vivo Hydrolysis of L-Asparagine by Asparaginase
125. Predictive Performance of a Physiologically Based Pharmacokinetic Model of Busulfan in Children
126. Sources of preanalytical error in pharmacokinetic analyses – focus on intravenous drug administration and collection of blood samples
127. Sports in Pediatric Oncology
128. Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar®in Children with Acute Lymphoblastic Leukemia
129. Comparison of self‐reported physical activity in children and adolescents before and during cancer treatment
130. A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia
131. Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients
132. Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis
133. Abstract 2219: The European Paediatric Oncology off-patent medicines Consortium (EPOC) pharmacokinetic/pharmacodynamic study of doxorubicin.
134. Risk and benefit from clinical trials in minors: Making the case for transparent and consistent publications
135. A Germline Mutation in Cathepsin B in a Child with ALL Points towards a Key Role for This Enzyme in L-Asparaginase Pharmacokinetics.
136. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy
137. Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring
138. Erratum: Methodological and ethical aspects of randomized controlled clinical trials in minors with malignant diseases
139. Population Pharmacokinetics of NativeEscherichia ColiAsparaginase
140. Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients
141. Minimization of the Preanalytical Error in Plasma Samples for Pharmacokinetic Analyses and Therapeutic Drug Monitoring - Using Doxorubicin as an Example
142. Anti–Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials
143. The Bone Marrow Niche of Patients with Acute Lymphoblastic Leukemia Produces No Increased Asparagine Levels In Vivo That May Lead to Clinical Asparaginase Resistance
144. Abstract C104: High in vitro sensitivity of pediatric solid and hematological malignancies to the survivin-suppressant YM155.
145. Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children
146. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children
147. An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies
148. Pediatric patients with a malignant bone tumor: when does functional assessment make sense?
149. Oral low‐dose chemotherapy: Successful treatment of an alveolar rhabdomyosarcoma during pregnancy
150. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.